| Name | Title | Contact Details |
|---|
Founded in 2006, Ocular Therapeutix is a fast-growing, aspiring leader in the biopharmaceutical industry. The company has a clear vision – to improve current therapeutic options in ophthalmology by encapsulating previously approved therapeutic agents in our novel hydrogel to provide a sustained delivery of drugs to the eye. We are reframing the industry with new modalities for ophthalmic therapies. As a small company, our employees are provided the unique opportunity to help build the foundation of the business as it grows. We strongly believe that our success is contingent upon the achievements of our employees. We strive to create a collaborative, challenging environment that encourages individuals to bring success to their career and the company. Through the use of our proprietary hydrogel technology, we strive to offer superior products that improve the world’s vision.
Corvia Medical, Inc. is revolutionizing the treatment of heart failure with a novel transcatheter structural heart device. Founded in 2009 and headquartered in Tewksbury, MA, Corvia Medical is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives.
EST Analytical is a Fairfield, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Integrity Applications is dedicated to developing breakthrough innovations in non-invasive glucose monitoring devices. Since its founding in 2001, Integrity Applications has been committed to improving the quality of life for people with diabetes by removing the obstacles of traditional invasive devices, namely painful pricking of fingertips, added costs as a result of disposables, as well as inconvenience. Integrity Applications has developed a state-of-the-art way to measure glucose levels using three non-invasive technologies, ultrasound, thermal, and electromagnetic in combination with a proprietary algorithm to produce a weighted glucose measurement. After proof of concept in 2002, Integrity Applications developed the first working prototype, GlucoTrack in August 2003. GlucoTrack® Model DF-F received CE Mark approval in June 2013 and KFDA in March 2016. GlucoTrack is currently being marketed in the European Union and in South Korea.
VeriChip Corporation is a Delray Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.